What are research peptides? The label and the vial
Research peptide is a sales label, not an FDA drug category. What research use only means in law, and what lab tests have found inside such vials.
Peptio Research
On this page7
"Research peptide" is a label used by sellers, not a regulatory category. None of the FDA documents opened for this page defines the term. Products sold this way usually carry a line such as "for research use only" or "not for human consumption". That phrase does have one defined meaning in US regulation, but it belongs to laboratory diagnostic products, not to drugs. When FDA has written to peptide sellers, the label did not decide how the product was treated. And one small published study of such products found three vials far below their stated purity.
Where "research use only" comes from
The defined version of the phrase sits in the rules for in vitro diagnostic products, meaning tests run on samples such as blood in a laboratory. For a diagnostic product "in the laboratory research phase of development", the labelling must read "For Research Use Only. Not for use in diagnostic procedures." 1 A product at the next stage carries "For Investigational Use Only. The performance characteristics of this product have not been established." 1
That regulation covers diagnostic products. No source found for this page says it applies to peptides sold to the public, and no equivalent research-use category for drugs was found.
What decides how FDA treats the product
FDA judges a product by its intended use, which a federal rule defines as "the objective intent of the persons legally responsible for the labeling of an article" 2. That intent "may, for example, be shown by labeling claims, advertising matter," "or oral or written statements by such persons or their representatives." 2 In other words, the label is one piece of evidence among several, not the last word.
Three warning letters to peptide sellers show the rule in use. A December 2024 letter noted products labelled "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY", then said "evidence obtained from your websites establish that your products are intended to be drugs for human use" 3. An August 2026 letter said: "Despite statements on your product labeling marketing your products "for research use only"", "evidence obtained from your website establishes that your products are intended to be drugs for human use." 4 A March 2026 letter, about products labelled for "laboratory research purposes only" and "not for human consumption, medical use or veterinary use", said their distribution "violates sections 301(d) and 505(a) of the FD&C Act" 5.
The passages quoted here concern intended use, not product testing. How FDA handles compounding, advisory committee votes and import alerts is covered in Is the FDA banning peptides?.
What FDA has said about such products
On a page about unapproved GLP-1 drugs, FDA says it has warned companies selling products "falsely labeled "for research purposes" or "not for human consumption."" 6 It says these have "been sold directly to consumers for human use with dosing instructions" 6. On quality, FDA says illegally marketed versions "could contain the wrong ingredients, contain too little, too much or no active ingredient at all" 6, and describes the products as "of unknown quality" 6. That is FDA's description of a risk, not a set of measurements. No comparable FDA statement about non-GLP-1 research peptides was found.
What laboratories have found inside
Very little has been measured. The most detailed study found is a test purchase published in 2024 7. The researchers bought semaglutide from online sellers. Three orders for pens were never delivered. Three freeze-dried vials, labelled "research use only", did arrive and were analysed. Measured semaglutide purity, the share of the powder that was semaglutide, ranged "between 7.7% and 14.37%", against "the 99% claimed on product labels" 7. Endotoxin "was detected in all samples" 7. The vials were "devoid of viable microorganisms at the time of testing" 7. The authors judged all three "probable substandard and falsified products" 7.
A Danish forensic laboratory analysed 36 samples of doping-related products seized in 2019 8. Nine contained no peptides or proteins at all. Fifteen contained an illegal doping substance, and 12 contained substances not on the Danish doping list 8. These were seized products, not specifically ones labelled for research.
Case reports
Two 2026 case reports each describe one patient who had used a product sold as retatrutide, which FDA says is not a component of any FDA-approved drug 6. One patient with type 1 diabetes presented with impending diabetic ketoacidosis alongside a gut infection, after using an "online-purchased product marketed as retatrutide for weight loss" 9. The other had refractory nausea after "an unverified product reported to contain retatrutide" 10. In neither case was the product analysed. Each is a single untested case. They show that people use these products and turn up in clinics; they show nothing about what the products contained or whether the product caused the illness.
What is not known
What is in most products sold as research peptides has not been measured in any published study found here. The evidence that exists covers a handful of GLP-1 vials and seized samples. It points to poor quality where testing was done, but it cannot say how common that is, and no study found links a specific defect in these products to measured harm in people.
Peptides covered
Research areas
Sources
- 1. 21 CFR 809.10 Labeling for in vitro diagnostic products. Electronic Code of Federal Regulations. 2026. View source(open access)
- 2. 21 CFR 201.128 Meaning of "intended uses". Electronic Code of Federal Regulations. 2026. View source(open access)
- 3. FDA Warning Letter, MARCS-CMS 695607, December 10, 2024. U.S. Food and Drug Administration. 2024. View source(open access)
- 4. FDA Warning Letter, MARCS-CMS 735063, August 24, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 5. FDA Warning Letter, MARCS-CMS 721805, March 31, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 6. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026. View source(open access)
- 7. Ashraf AR et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research. 2024. PubMed 39509151(open access)
- 8. Høj LJ et al. Analysis of seized peptide and protein-based doping agents using four complimentary methods: Liquid chromatography coupled with time of flight mass spectrometry, liquid chromatography-ultraviolet, Bradford, and immunoassays. Drug Testing and Analysis. 2021. PubMed 33686802
- 9. Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. 2026. PubMed 42669023(open access)
- 10. Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Reports. 2026. PubMed 42843917(open access)